<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>16(11)</volume><submitter>Cherney DZI</submitter><funding>Boehringer Ingelheim &amp;amp; Eli Lilly and Company Diabetes Alliance</funding><journal>Clinical journal of the American Society of Nephrology : CJASN</journal><pagination>1715-1719</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8729416</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Kidney Effects of Empagliflozin in People with Type 1 Diabetes.</pubmed_title><pmcid>PMC8729416</pmcid><pubmed_authors>Neubacher D</pubmed_authors><pubmed_authors>Cherney DZI</pubmed_authors><pubmed_authors>Marquard J</pubmed_authors><pubmed_authors>Rosenstock J</pubmed_authors><pubmed_authors>Bjornstad P</pubmed_authors><pubmed_authors>Perkins BA</pubmed_authors><pubmed_authors>Soleymanlou N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Kidney Effects of Empagliflozin in People with Type 1 Diabetes.</name><description/><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Nov</publication><modification>2025-04-04T22:33:49.981Z</modification><creation>2025-02-19T03:24:03.913Z</creation></dates><accession>S-EPMC8729416</accession><cross_references><pubmed>34535454</pubmed><doi>10.2215/cjn.07700621</doi><doi>10.2215/CJN.07700621</doi></cross_references></HashMap>